Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses
Open Access
- 11 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15), 3572-3585
- https://doi.org/10.1182/bloodadvances.2019001410
Abstract
Immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide, are widely used treatments for multiple myeloma; however, they occasionally lead to episodes of itchy skin and rashes. Here, we analyzed the effects of IMiDs on human myeloid dendritic cells (mDCs) as major regulators of Th1 or Th2 responses and the role they play in allergy. We found that lenalidomide and pomalidomide used at clinical concentrations did not affect the survival or CD86and OX40-ligand expression of blood mDCs in response to lipopolysaccharide (LPS) and thymic stromal lymphopoietin (TSLP) stimulation. Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS. When stimulated with TSLP, both IMiDs significantly enhanced CCL17 production and STAT6 and IRF4 expression and promoted memory Th2-cell responses. In 46 myeloma patients, serum CCL17 levels at the onset of lenalidomide-associated rash were significantly higher than those without rashes during lenalidomide treatment and those before treatment. Furthermore, serum CCL17 levels in patients who achieved a very good partial response (VGPR) were significantly higher compared with a less than VGPR during lenalidomide treatment. The median time to next treatment was significantly longer in lenalidomide-treated patients with rashes than those without. Collectively, IMiDs suppressed the Th1-inducing capacity of DCs, instead promoting a Th2 response. Thus, the lenalidomide-associated rashes might be a result of an allergic response driven by Th2-axis activation. Our findings suggest clinical efficacy and rashes as a side effect of IMiDs are inextricably linked through immunostimulation.This publication has 84 references indexed in Scilit:
- Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple MyelomaPLOS ONE, 2012
- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myelomaBritish Journal of Cancer, 2012
- The prostaglandin D2 receptor CRTH2 is important for allergic skin inflammation after epicutaneous antigen challengeJournal of Allergy and Clinical Immunology, 2010
- Sensing the outside world: TSLP regulates barrier immunityNature Immunology, 2010
- Distinct Signal Codes Generate Dendritic Cell Functional PlasticityScience Signaling, 2010
- Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4Blood, 2010
- Signal Transducer and Activator of Transcription 4 Is Required for the Transcription Factor T-bet to Promote T Helper 1 Cell-Fate DeterminationImmunity, 2008
- In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammationJCI Insight, 2007
- Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitisProceedings of the National Academy of Sciences of the United States of America, 2006
- Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLPNature Immunology, 2002